Quick Answer
Actinium Pharmaceuticals, Inc. reported Operating Income of -$36.25 million for fiscal year 2025.
Actinium Pharmaceuticals, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$36.25M | +13.9% |
| 2024 | -$42.12M | +18.9% |
| 2023 | -$51.92M | -52.2% |
| 2022 | -$34.10M | -36.6% |
| 2021 | -$24.96M | -11.5% |
| 2020 | -$22.39M | -1.5% |
| 2019 | -$22.07M | +7.4% |
| 2018 | -$23.83M | +11.5% |
| 2017 | -$26.91M | -0.2% |
| 2016 | -$26.85M | -8.1% |
| 2015 | -$24.83M | -10.5% |
| 2014 | -$22.48M | -241.0% |
| 2013 | -$6.59M | +17.1% |
| 2012 | -$7.95M | -142.0% |
| 2011 | -$3.28M | -12503.8% |
| 2010 | -$26.1K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$5.69M | +54.8% | +24.1% |
| June 30, 2025 | -$7.50M | +39.6% | +54.9% |
| March 31, 2025 | -$16.64M | -73.4% | -32.0% |
| September 30, 2024 | -$12.60M | +12.2% | -1.5% |
| June 30, 2024 | -$12.42M | +20.6% | -29.4% |
| March 31, 2024 | -$9.60M | +17.2% | +33.1% |
| September 30, 2023 | -$14.35M | -46.5% | +8.3% |
| June 30, 2023 | -$15.64M | -99.3% | -35.0% |
- Actinium Pharmaceuticals, Inc. showed an increase of +13.9% in Operating Income compared to the prior fiscal year.
- Over the 2010–2025 period, Actinium Pharmaceuticals, Inc.’s operating income has declined by 139027.9% (from -$26.1 thousand to -$36.25 million).
- The most recent figure is from Actinium Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: